New KRAS-Targeting Drugs Offer Hope for Pancreatic Cancer Patients
Researchers and pharmaceutical companies are racing to develop drugs targeting KRAS, a gene mutation that drives aggressive cancers including metastatic pancreatic cancer. For patients like 36-year-old Leanna Stokes of New Rochelle, New York, KRAS mutations represent both a challenge and a potential therapeutic target. The emerging class of KRAS inhibitors is being described as among the most promising oncology treatments in decades.
რეკლამა: Article Inline